What Happened
The Partnership for Safe Medicines (PSM), a nonprofit coalition focused on substandard medicines, has asked the US Food and Drug Administration to block compounding of seven peptide substances and to disregard the advisory vote that recommended allowing six of them.
The citizen petition was filed Friday, October 16, 2026, and publicized the following week. It names BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon: the seven compounds the FDA's Pharmacy Compounding Advisory Committee (PCAC) took up on July 23-24, where agency scientists recommended against all seven on characterization and safety grounds. The committee voted the other way on six, rejecting only emideltide (DSIP). No proposed rule followed.
PSM argues the vote should not inform future rulemaking because the committee, in its reading, was constituted in violation of the Federal Advisory Committee Act and the Ethics in Government Act, which police conflicts of interest. Newly appointed members, it says, include people with financial ties to the peptide industry.
"The only people who stand to benefit from allowing these peptides to be compounded are those who are doing the selling," PSM executive director Shabbir Imber Safdar said in a statement accompanying the filing.
The group also published a purchase test: five vials bought over six weeks through telehealth sellers arrived from four licensed 503A pharmacies in Texas and Pennsylvania, none labeled "research use only" and all shipped with syringes and injection instructions. Complaints are now pending with state boards of pharmacy and the FDA's Office of Criminal Investigation.
Who Is Affected
- Patients buying through telehealth — licensed pharmacies, not anonymous gray-market sites, are supplying these vials with human-use labeling.
- 503A compounders and their prescribers — a granted petition closes a revenue line; a denial leaves the July vote intact but still not law.
- Gray-market buyers — unapproved vials sold online are unaffected either way.
- Researchers — a formal administrative record and a decision clock now exist where there was only an unresolved vote.
Timeline
- July 23-24, 2026 — PCAC reviews seven peptide bulk substances; FDA staff oppose all seven, the committee endorses six.
- October 16, 2026 — PSM files its citizen petition under 21 CFR 10.30.
- October 21, 2026 — The filing is announced publicly.
- By April 14, 2027 — FDA must respond within 180 days of filing.
What This Means for Researchers
A citizen petition does not change the legal status of any peptide. It forces the arguments onto the administrative record and obliges the agency to answer, which matters because no rule has appeared since July.
Either outcome is possible: the agency can decline the petition and proceed with rulemaking, or accept the procedural argument and treat the July vote as tainted. A 503A listing would permit compounding for identified patients under prescription — not retail manufacturing, and not a safety finding.
How to Verify Your Peptides
If you already hold vials, the questions that matter are identity, purity, fill weight and sterility. Our testing guides cover what a certificate of analysis should contain and how to read a lab report: How testing works, HPLC vs LC-MS, Identity, purity and fill weight.
Safe Alternatives
None of the seven substances is an FDA-approved drug, so there is no approved version to substitute. Read the evidence base before spending money — our guides on BPC-157, TB-500, MOTS-c, KPV and Semax separate human trial data from animal and in-vitro work — and buy only from suppliers with published third-party testing in our vendor directory.
Sources
- PSM citizen petition, filed October 16, 2026 (21 CFR 10.30)
- Regulatory announcements, July 2026 PCAC meeting
- Industry reports on 503A compounding enforcement, October 2026